DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 20.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,014 shares of the medical device company's stock after purchasing an additional 3,547 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in DexCom were worth $1,635,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter worth $25,000. Private Trust Co. NA lifted its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares during the last quarter. TD Private Client Wealth LLC boosted its stake in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. Larson Financial Group LLC increased its position in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new position in DexCom in the 4th quarter valued at approximately $38,000. 97.75% of the stock is owned by institutional investors.

DexCom Trading Down 1.6 %

Shares of NASDAQ:DXCM traded down $1.12 during trading on Thursday, reaching $70.26. 6,865,096 shares of the company were exchanged, compared to its average volume of 4,217,704. The business's fifty day simple moving average is $72.01 and its 200-day simple moving average is $76.67. The firm has a market capitalization of $27.55 billion, a PE ratio of 49.13, a P/E/G ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $132.26. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on DXCM shares. Robert W. Baird upgraded DexCom from a "neutral" rating to an "outperform" rating and increased their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group boosted their price target on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Mizuho started coverage on shares of DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price on the stock. Finally, Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $99.00.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares in the company, valued at $10,002,636.06. This trade represents a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at $26,183,401.02. The trade was a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,926 shares of company stock worth $4,734,384 over the last quarter. 0.32% of the stock is currently owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.